促黄体生成激素释放激素（LH-RH）激动剂和拮抗剂类似物在晚期前列腺癌治疗中的现状
Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.
作者信息
Schally A V, Comaru-Schally A M, Gonzalez-Barcena D
机构信息
Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112.
出版信息
Biomed Pharmacother. 1992;46(10):465-71. doi: 10.1016/0753-3322(92)90004-q.
The methods for treatment of advanced prostate cancer, based on the agonistic analogs of LH-RH were reviewed. New therapeutic approaches utilizing antagonistic analogs of LH-RH such as SB-75 (Cetrorelix) have been described. Analogs of LH-RH chemically linked to various cytotoxic radicals are also being developed. Combinations of LH-RH agonists or antagonists with superactive somatostatin analogues such as Octastatin (RC-160) or with bombesin/GRP antagonists are being investigated in order to delay or prevent the relapse and improve the therapy for prostate cancer.
综述了基于促性腺激素释放激素（LH-RH）激动剂类似物治疗晚期前列腺癌的方法。已描述了利用LH-RH拮抗剂类似物（如SB-75，西曲瑞克）的新治疗方法。与各种细胞毒性基团化学连接的LH-RH类似物也在研发中。正在研究LH-RH激动剂或拮抗剂与超活性生长抑素类似物（如奥曲肽，RC-160）或与蛙皮素/胃泌素释放肽（GRP）拮抗剂的联合应用，以延迟或预防复发并改善前列腺癌的治疗。
Zotero 插件